Dozens of medications are approved for major depressive disorder (MDD), spanning several drug classes that work through different brain pathways. The most commonly prescribed are selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), but the full toolkit includes older drugs like tricyclics and monoamine oxidase inhibitors, atypical agents like bupropion and mirtazapine, and a newer wave of fast-acting treatments targeting glutamate and GABA signaling. Choosing between them is rarely straightforward, because real-world remission rates vary widely depending on a person’s medical history, symptom profile, and even genetics.
The Mainstay Classes and How They Differ
SSRIs, including fluoxetine, sertraline, escitalopram, and paroxetine, remain the first-line choice for most people starting treatment. They block the reabsorption of serotonin in the brain, leaving more of it available in the synaptic gap between nerve cells. SNRIs like venlafaxine and duloxetine do the same for both serotonin and norepinephrine. Tricyclic antidepressants (TCAs), an older class, also block reuptake of these neurotransmitters but hit additional receptor systems, which is why they tend to produce more side effects like dry mouth, constipation, and sedation. All three classes share a core limitation: they take several weeks to produce their full clinical effect.
Monoamine oxidase inhibitors (MAOIs) are the oldest antidepressant class and among the least prescribed today, though they can be remarkably effective for people who haven’t responded to other options. MAOIs work by blocking the enzyme that breaks down serotonin, norepinephrine, and dopamine. The tradeoff is serious dietary and drug restrictions. The enzyme MAO-A normally prevents norepinephrine from building up to dangerous levels; when it’s inhibited, eating tyramine-rich foods like aged cheese or cured meats can trigger life-threatening blood pressure spikes with as little as 8 to 10 milligrams of tyramine ingested.1PubMed Central. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors MAOIs also interact dangerously with many common medications, including other antidepressants and certain cold remedies.
Why Most Antidepressants Take Weeks to Work
One of the most frustrating aspects of starting an antidepressant is the delay. SSRIs, SNRIs, and tricyclics typically need several weeks before someone feels meaningfully better. This lag puzzled researchers for years, because these drugs change neurotransmitter levels within hours of the first dose. The explanation lies deeper than simple chemistry. The clinical effects depend on the brain gradually remodeling itself in response to the sustained chemical signal.2PubMed Central. Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways
Chronic stress and depression are associated with physical changes in brain tissue: loss of connections between nerve cells, shrinking of branching structures in the hippocampus and prefrontal cortex, and even a decrease in supporting glial cells.3Europe PMC. How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy Antidepressants gradually protect against and reverse some of these changes, promoting the growth of new synaptic connections. That rewiring process, not the initial serotonin boost, appears to be what actually produces improvement. This is why the old idea that depression is simply a “chemical imbalance” of serotonin was too simplistic to explain therapeutic response.4PubMed Central. Cellular and molecular mechanisms in the long-term action of antidepressants
Matching the Drug to the Symptom Profile
Not every antidepressant affects every depression symptom equally. Two “atypical” antidepressants, bupropion and mirtazapine, illustrate this particularly well. Bupropion works primarily on dopamine and norepinephrine rather than serotonin and tends to be activating rather than sedating. It performs best for people whose depression features oversleeping, weight gain, increased appetite, or fatigue. Mirtazapine, by contrast, is sedating and appetite-stimulating, making it a better fit for people dealing with insomnia, weight loss, or poor appetite.5PubMed. Consistent differential effects of bupropion and mirtazapine in major depression
Bupropion also carries a unique side effect concern. At immediate-release doses above 450 milligrams per day, seizure risk rises roughly tenfold. However, sustained-release formulations at standard doses brought the seizure rate down to about 0.1%, which is comparable to SSRIs and to the general population’s background rate.6Chonnam Medical Journal. Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review For many people, bupropion’s most appealing quality is that it avoids the weight gain and sexual side effects common with serotonin-based drugs.
The New Wave of Faster-Acting Treatments
The weeks-long wait for traditional antidepressants to kick in has driven intense interest in drugs that work faster. The breakthrough came from an unlikely source: ketamine, an anesthetic that has been around since the 1960s. At subanesthetic doses, ketamine blocks a specific type of glutamate receptor in the brain, triggering a cascade that promotes rapid formation of new synaptic connections, particularly in the prefrontal cortex.7PubMed Central. Ketamine’s Mechanism of Action: A Path to Rapid-Acting Antidepressants People with treatment-resistant depression sometimes experience improvement within hours of a single infusion, a timeline that was essentially unheard of before ketamine research began.8Neuropsychopharmacology. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms
Esketamine, a nasal spray form of one of ketamine’s mirror-image molecules, became the first FDA-approved ketamine-derived treatment for treatment-resistant depression. It must be administered in a certified healthcare setting, with the patient monitored for at least two hours afterward due to potential dissociation and sedation. Intravenous ketamine is used off-label in specialty clinics and appears to produce slightly more quality-adjusted life years than esketamine at lower cost, though esketamine’s approval gives it a regulatory framework that ketamine infusion clinics lack.9PubMed Central. Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates
Another recent addition is dextromethorphan-bupropion, an oral pill that combines a glutamate-targeting compound (dextromethorphan, the ingredient in some cough syrups) with bupropion, which here serves mainly to slow dextromethorphan’s breakdown in the body. In clinical trials, people taking this combination saw measurable improvement within two weeks, and long-term studies showed remission rates approaching 70% and response rates above 80% over 12 to 15 months.10PubMed Central. Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder The drug was generally well tolerated, with most side effects rated mild to moderate.
Postpartum Depression Gets Its Own Drug Class
Postpartum depression has historically been treated with the same SSRIs and SNRIs used for general MDD. That changed with the development of neurosteroid drugs that modulate GABA receptors. Brexanolone was the first, but it required a 60-hour intravenous infusion in a certified facility. Zuranolone, a pill taken orally for just 14 days, followed and removed most of those logistical barriers.11PubMed Central. Zuranolone for the Treatment of Postpartum Depression A Cochrane review found moderate-certainty evidence that zuranolone improved depression response and remission at 45 days from starting treatment, though early results at 30 days were less convincing.12Cochrane Database of Systematic Reviews. Neurosteroid GABAA receptor positive allosteric modulators for postnatal depression
When the First Drug Fails
A large real-world study found that remission rates for antidepressants varied enormously depending on a patient’s age, sex, and medical history. In some subgroups, the best-performing antidepressant achieved remission in about half of patients, while the worst performer had a remission rate 20 times lower. The average across all drugs was around 30%.13eClinicalMedicine. Effectiveness of common antidepressants: a post market release study That means for any given drug, more people will not fully recover than will. This is not a failure of the drugs so much as a reflection of how heterogeneous depression is.
When the first and second medications fail, doctors often add an augmenting agent rather than switching yet again. Lithium remains one of the most cost-effective augmentation options, with a well-established efficacy profile and the added benefit of reducing impulsivity and suicide risk.14PubMed Central. Lithium Augmentation in Treatment-Resistant Depression: A Qualitative Review of the Literature It does require regular blood monitoring because of a narrow range between effective and toxic doses. Second-generation antipsychotics like quetiapine and aripiprazole are also frequently added. Esketamine is reserved for people who have failed multiple adequate trials. Each of these options has a distinct monitoring burden and side effect profile, so the choice depends on the clinical picture and practical feasibility.15PubMed. Pharmacological augmentation in treatment-resistant depression: a neurobiologically informed, practical decision guide for treatment choice with lithium, quetiapine, or esketamine
By the time someone has failed three or more medication trials, remission rates with further pharmacology alone become discouraging. In one arm of the landmark STAR*D trial, patients who had already failed three adequate treatments and then received either the MAOI tranylcypromine or a combination of venlafaxine plus mirtazapine achieved remission rates of only about 7% and 14%, respectively.16PubMed. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report This is why treatment-resistant depression has become a distinct clinical category with its own treatment algorithms, including ketamine-based therapies and brain stimulation.
Side Effects That Shape Real-World Decisions
In theory, the “best” antidepressant is the most effective one. In practice, side effects often dictate what people can tolerate long enough to benefit from. Sexual dysfunction is one of the most common and most underreported problems with serotonin-based antidepressants. Reported issues range from decreased desire and difficulty with arousal to delayed or absent orgasm, and they can significantly affect quality of life, relationships, and willingness to stay on the medication.17PubMed Central. Antidepressant-associated sexual dysfunction: impact, effects, and treatment Bupropion and mirtazapine are often chosen specifically because they tend to spare sexual function.
Weight gain is another common reason people stop their medication. SSRIs like paroxetine and mirtazapine are among the worst offenders, while bupropion is weight-neutral or slightly weight-reducing. Sedation, nausea, and emotional blunting round out the list of effects that, while not medically dangerous, erode a person’s willingness to keep taking pills every day. These tolerability differences matter more than they might seem; an antidepressant that someone actually takes consistently is far more useful than a theoretically superior one that ends up in the medicine cabinet after three weeks.
Stopping Antidepressants Safely
Discontinuing an antidepressant, especially an SSRI or SNRI, can produce its own unpleasant symptoms. A 2025 meta-analysis found that stopping antidepressants was associated with increased dizziness, nausea, vertigo, and nervousness compared to people discontinuing a placebo. Dizziness was the most common withdrawal symptom. The overall effect translated to roughly one additional symptom on a standardized checklist, though individual experiences varied widely. Interestingly, discontinuation was not associated with a worsening of depression symptoms in the short term.18JAMA Psychiatry. Incidence and Nature of Antidepressant Discontinuation Symptoms: A Systematic Review and Meta-Analysis The standard advice to taper gradually rather than stopping abruptly is well supported, and short-half-life drugs like paroxetine and venlafaxine tend to produce the worst withdrawal if stopped suddenly.
Serotonin Syndrome
One serious risk that crosses multiple drug classes is serotonin syndrome, a potentially life-threatening reaction caused by too much serotonin activity in the brain and body. Symptoms include muscle twitching or rigidity, rapid heart rate, sweating, agitation, and in severe cases, dangerously high fever and seizures.19PubMed Central. Serotonin syndrome It most often occurs when two or more serotonin-boosting drugs are combined, particularly an MAOI with an SSRI or SNRI.20PubMed Central. Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions But it can also happen from a single serotonergic drug at high doses or even at therapeutic doses in a susceptible person.21PubMed. Serotonin syndrome-A focused review This is why washout periods between stopping an MAOI and starting an SSRI (or vice versa) are taken so seriously, and why providers need to know about every medication and supplement a patient is taking, including over-the-counter migraine drugs and the herbal supplement St. John’s wort.
Children, Pregnancy, and Older Adults
Antidepressant prescribing gets more complicated in certain populations. For children and adolescents, the FDA’s black box warning about a possible increased risk of suicidal thoughts has shaped prescribing habits since 2004. The warning was based on short-term industry-sponsored trials showing a modest increase in suicidal ideation (not completed suicides) in young people taking antidepressants compared to placebo.22PubMed Central. The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits? The controversy has only grown since. A systematic review found that the intended effect of the warning, increased physician monitoring of suicidal thoughts, did not materialize. Instead, multiple studies found significant unintended drops in mental health care utilization, followed by marked increases in drug poisonings (a proxy for suicide attempts) and suicide deaths.23PubMed. Intended And Unintended Outcomes After FDA Pediatric Antidepressant Warnings: A Systematic Review Some researchers have argued the warnings were based on biased data and have done more harm than good, though the debate remains open.24PubMed. Antidepressant drugs and the risk of suicide in children and adolescents
During pregnancy, the decision to use antidepressants involves weighing competing risks. SSRIs have been associated in meta-analyses with small increases in the risk of congenital heart defects (particularly with paroxetine and fluoxetine), preterm birth, and neonatal adaptation problems like jitteriness and breathing difficulties in the newborn.25PubMed. Benefits and Risks of Antidepressant Drugs During Pregnancy: A Systematic Review of Meta-analyses But untreated depression during pregnancy carries its own dangers, including higher risk of preeclampsia and subsequent postnatal depression, which can harm both the mother and the developing bond with the child.26PubMed Central. Risks of using SSRI / SNRI antidepressants during pregnancy and lactation One reassuring finding from a critical review is that the associations between prenatal antidepressant exposure and neurodevelopmental conditions like autism and ADHD in children appear to be largely explained by confounding factors rather than by the medication itself.27PubMed Central. Annual Research Review: Maternal antidepressant use during pregnancy and offspring neurodevelopmental problems – a critical review and recommendations for future research
Older adults face a different set of concerns. Antidepressants, SSRIs in particular, can lower blood sodium levels, a condition called hyponatremia. In elderly patients, the prevalence of this side effect runs around 9%, with the risk climbing higher in people who weigh less than about 130 pounds or who have experienced low sodium before.28PubMed. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study The risk increases further when SSRIs are combined with thiazide diuretics, a common blood pressure medication, pushing hyponatremia prevalence to about 13%.29PubMed Central. Evaluation of hyponatremia among older adults exposed to selective serotonin reuptake inhibitors and thiazide diuretics Symptoms of low sodium can mimic or worsen depression itself, including confusion, fatigue, and unsteadiness, so this is worth monitoring.
Pharmacogenomic Testing
One of the more promising developments in depression treatment is pharmacogenomic testing, which examines a patient’s genetic variants in liver enzymes that metabolize antidepressants. The idea is simple: if your body breaks down a drug unusually fast, you may not get enough of it; if you break it down unusually slowly, you may accumulate too much and experience more side effects. A meta-analysis of randomized controlled trials found that pharmacogenomic-guided prescribing improved remission rates compared to standard treatment, with odds of remission roughly 85% higher in the guided group.30PubMed. Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trials
The picture is more nuanced than that headline suggests. An earlier study found that while genetic variants in these enzymes reliably predicted blood levels of certain antidepressants, the difference in blood levels did not always translate into differences in clinical response.31PubMed. Genetic differences in cytochrome P450 enzymes and antidepressant treatment response More recent work with sertraline specifically showed that different metabolizer types did respond differently, but the fastest metabolizers (who cleared the drug most efficiently) also had the poorest treatment outcomes, while the slowest metabolizers got better results but experienced more side effects and were less likely to stick with treatment.32PubMed Central. Exploring the Effect of Genetic Testing on Personalised Treatment Plans for Depression The practical takeaway is that these tests can help guide dose adjustments and drug selection, but they are not yet a crystal ball for predicting who will respond to what.
The Placebo Problem in Antidepressant Research
Antidepressant clinical trials are haunted by an unusual challenge: people in the placebo group keep getting better. Placebo response in depression trials has been substantial for decades and has been climbing steadily, growing by about 6% since 2000.33PubMed Central. Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013 This has made it harder to prove that new drugs work better than sugar pills, delaying approval of potentially useful treatments.34PubMed Central. A model of placebo response in antidepressant clinical trials
However, something interesting emerged from a closer look at FDA data spanning 1987 to 2013: drug response has risen by a similar amount over the same period. The actual gap between drug and placebo has stayed essentially flat, with effect sizes around 0.30 in both earlier and later eras, and the percentage of trial arms that came out positive has actually trended upward.35PubMed Central. Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013 This means that while the rising placebo response makes headlines, it may not actually be sabotaging trial outcomes as badly as people assume. The drugs still separate from placebo by about the same margin they always have.
Psilocybin and the Psychedelic Pipeline
Psilocybin, the active compound in “magic mushrooms,” has generated considerable excitement in depression research. Early phase II trials have shown large, rapid, and persistent effects in treatment-resistant depression and depression associated with terminal illness, and the mechanism appears distinct from how SSRIs work.36PubMed. Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review An exploratory placebo-controlled trial found that psilocybin-assisted therapy significantly improved psychological flexibility and acceptance, and that these changes were strongly associated with reductions in depression severity that lasted through 16 weeks.37PubMed Central. Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial
Psilocybin is not yet FDA-approved for depression, and the research is still in relatively early stages. The treatment model looks nothing like conventional prescribing: it involves one or two dosing sessions in a therapeutic setting with trained facilitators, bracketed by preparatory and integration psychotherapy. Whether this model can be scaled affordably, whether the effects hold up in larger and more diverse populations, and whether regulators will approve a Schedule I compound for routine psychiatric use all remain open questions. But the trajectory of the research suggests that the pharmacological toolkit for depression is still expanding in genuinely new directions.
The Gut Connection
A growing area of interest is the relationship between antidepressants and the gut microbiome. Most of the body’s serotonin is actually produced in the gut, not the brain, and SSRIs affect nerve cells in the digestive tract as well as in the central nervous system. SSRIs also have antimicrobial properties, meaning they can alter the composition of gut bacteria.38Frontiers in Psychiatry. Serotonin Reuptake Inhibitors and the Gut Microbiome: Significance of the Gut Microbiome in Relation to Mechanism of Action, Treatment Response, Side Effects, and Tachyphylaxis This has led researchers to wonder whether individual differences in gut flora might help explain why the same drug works brilliantly in one person and does nothing in another. It might also shed light on tachyphylaxis, the phenomenon where a drug that initially helped stops working. The science here is still in early stages, with more questions than answers, but it represents one of the more intriguing frontiers in understanding why predicting antidepressant response remains so difficult.